Chong Kun Dang announced on Tuesday that its over-the-counter skin treatment, Dermagram PDRN Cream, has been featured as a recommended product for foreign tourists on the Korea Tourism Organization’s official tourism information portal.
The company revealed that Dermagram PDRN Cream has been showcased as a K-pharmacy shopping item on VISITKOREA, the Korea Tourism Organization’s official foreign language tourism portal.
Recently, foreign tourists visiting Korea have been expanding their shopping habits from drugstores and duty-free shops to local pharmacies. With the growing interest in K-beauty, pharmaceuticals and skincare products available in Korean pharmacies are emerging as new must-buy items for tourists.
In a September column titled, Essential Korean Travel Experience: K-Pharmacy Shopping, the Korea Tourism Organization highlighted products that foreign visitors should consider purchasing at Korean pharmacies. The article spotlighted pharmacy skincare as a new travel trend, recommending Dermagram PDRN Cream for tourists interested in skin barrier care.
Dermagram PDRN Cream is an over-the-counter product formulated with PDRN, a skin tissue regeneration ingredient sourced from salmon. It provides nourishment to areas susceptible to wounds and ulcers due to nutrient deficiency in the skin and connective tissue, promoting the healing of damaged skin.
Chong Kun Dang emphasized that their patented purification process allows them to produce PDRN in a low-molecular-weight, high-purity form.
A Chong Kun Dang spokesperson stated that the Korea Tourism Organization’s recommendation demonstrates that international consumer interest is expanding beyond cosmetics to include over-the-counter products developed by Korean pharmaceutical companies. It’s committed to offering trusted skin health solutions to consumers globally, leveraging the advanced technology and quality competitiveness.
In related news, Chong Kun Dang has been making strategic moves in the biopharmaceutical contract development and manufacturing organization (CDMO) sector.
The CDMO field is seen as a gateway to enhanced collaboration with global pharmaceutical companies and increased opportunities for international market expansion, beyond mere production capabilities.
As the biopharmaceutical market experiences rapid growth, production capacity has become a key competitive advantage. Chong Kun Dang’s proactive investment strategy aims to meet future demand in this burgeoning sector.
